Medi Assist Healthcare Services Limited (MEDIASSIST) Fair Value & Analysis
Healthcare · IN · Market cap ₹28.1B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +2.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹297.74 – ₹586.50 · fair‑value band ₹163.07 – ₹281.58 · the ₹375.95 price screens above the ₹226.12 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medi Assist Healthcare Services Limited (MEDIASSIST) currently trades at ₹375.95, while our model-based Fair Value estimate is ₹226.12 — implying the stock looks roughly 39.9% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Medi Assist Healthcare Services Limited generated revenue of ₹9.0B at a net margin of 9.7%. Revenue grew 28.1% year over year. It earns a return on equity of 12.7%. The balance sheet holds a net cash position of ₹319M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Medi Assist Healthcare Services Limited, together with its subsidiaries, provides third party administration services in India and internationally. The company offers business support, health management, consultancy, contact center support, and other allied services related to the healthcare and health insurance sector. It also provides; and policy administration services to governments to enable public health schemes. The company was incorporated in 2000 and is headquartered in Bengaluru, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medi Assist Healthcare Services Limited reported revenue of ₹9.0B in FY2025 versus ₹3.9B in FY2021, a compound +23.1%/yr. Reported net income was ₹879M in FY2025, compounding +8.2%/yr from FY2021.
Is MEDIASSIST fairly valued? → Check now
Similar stocks
6 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| UnitedHealth Group UNH | 7,169 MXN | 292.06 MXN | -96% |
| CVS Health Corporation CVS | C$23.81 | C$17.91 | -25% |
| Elevance Health, Inc E1LV34 | R$421.98 | R$340.32 | -19% |
| The Cigna Group CI | $282.08 | $495.42 | +76% |
| Humana Inc HUM | $364.46 | $126.93 | -65% |
| Molina Healthcare, Inc MOH | $190.86 | $179.40 | -6% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medi Assist Healthcare Services Limited (MEDIASSIST) undervalued?
What is the fair value of MEDIASSIST?
What is the quality score of MEDIASSIST?
What is the revenue of Medi Assist Healthcare Services Limited (MEDIASSIST)?
What is the net profit margin of MEDIASSIST?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.